FCM
AMRX icon

Fieldview Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Fieldview Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,971
Closed -$163K – 484
2025
Q4 		$163K Buy
+12,971
New +$148K 0.03% 468

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Fieldview Capital Management's AMRX Position: Q1 2026 in Review

Fieldview Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 12,971 shares — an estimated $163K sold.

Fieldview Capital Management first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $163K in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Fieldview Capital Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 12,971 Amneal Pharmaceuticals shares in Q1 2026, an estimated $163K.
  • Fieldview Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Fieldview Capital Management's Amneal Pharmaceuticals position peaked at $163K in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.